The mycobacterial cell envelope — a moving target
The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index; 98 of the 127 sources its claims cite were checked for support.
Abstract
Mycobacterium tuberculosis, the leading cause of death due to infection, has a dynamic and immunomodulatory cell envelope. The cell envelope structurally and functionally varies across the length of the cell and during the infection process. This variability allows the bacterium to manipulate the human immune system, tolerate antibiotic treatment and adapt to the variable host environment. Much of what we know about the mycobacterial cell envelope has been gleaned from model actinobacterial species, or model conditions such as growth in vitro, in macrophages and in the mouse. In this Review, we combine data from different experimental systems to build a model of the dynamics of the mycobacterial cell envelope across space and time. We describe the regulatory pathways that control metabolism of the cell wall and surface lipids in M. tuberculosis during growth and stasis, and speculate about how this regulation might affect antibiotic susceptibility and interactions with the immune system.
Overview
CoChat Summary
TL;DR
This Review synthesizes data from model mycobacterial systems to argue that the *Mycobacterium tuberculosis* cell envelope is a spatially and temporally dynamic structure whose composition shifts between active growth and growth stasis. The authors propose that these envelope changes modulate immune interactions and antibiotic susceptibility, and that targeting stasis-active cell wall processes could shorten treatment.
Key findings
- The envelope is spatially organized: mycobacteria lack MreB and elongate asymmetrically at the poles (old pole growing faster), with d–d peptidoglycan crosslinks at poles/septum and more l–d crosslinks mid-cell; daughter cells differ in growth rate, size and macromolecule distribution.
- The authors model a growth-to-stasis shift in envelope composition: during active growth, peptidoglycan, arabinogalactan, mycolic acid metabolism, PIMs, TDM/TMM and PDIM are relatively abundant; in stasis, core wall metabolism decreases and shifts toward remodelling, PIMs/TDM/TMM/PDIM decrease, and LMs and LAMs become abundant.
- Regulatory control is kinase-centric: PknB is described as the master upstream regulator of peptidoglycan metabolism during growth (acting via CwlM–MurA, MviN–FhaA and PonA1), while its transcriptional downregulation in stationary phase, starvation and hypoxia is linked to reduced wall permeability and increased antibiotic tolerance; PonA1 complexes are proposed to dominate in active growth and PonA2 complexes in stasis.
- The mycomembrane makes the envelope 100–1,000 times less permeable to β-lactam antibiotics than the Gram-negative envelope; oxygenated meromycolates promote rifampicin tolerance in biofilms and increase resistance to several antibiotics, whereas cis-cyclopropanes have no effect or slightly promote sensitivity.
Methods
- Narrative Review combining data from different experimental systems (in vitro culture, macrophage infection, mouse, guinea pig and primate models, plus sputum and explanted human lung samples) to build a model of cell envelope dynamics across space and time.
- The authors state three simplifying assumptions: (1) *M. tuberculosis* shows two broad behaviours — rapid growth and growth stasis; (2) early infection can be modelled by in vitro stressors at sub-growth-blocking concentrations, early mouse infection and macrophage experiments; (3) stasis (growth and death in equilibrium, not arrested growth) can be modelled by chronic mouse infection and in vitro starvation, late stationary phase and oxygen deprivation.
- No primary data collection or statistical analysis is reported; the work interprets published biochemical, structural, transcriptional, transposon-sequencing and infection data.
Limitations
- Stated: it is "extremely difficult to study bacterial physiology during human infection"; available human material (sputum, explanted lungs) represents narrow subpopulations, and tools to study cell wall remodelling in these samples are very limited; in vitro and animal models cannot replicate the variability of human infection progression.
- Stated: ultrastructure and protein localization studies are mostly limited to logarithmic-phase culture, so it is not possible to say how spatial organization and asymmetry differ under infection stresses.
- Evident from the text: many conclusions are explicitly speculative ("we predict", "we propose", "in our model"), and the authors note that mechanisms of division site selection are poorly understood with conflicting observations, and that how *M. tuberculosis* uses asymmetric growth and remodelling during different infection stages is unknown.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
52 Valid · 6 Not valid · 14 Not checked · 20 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“The FAS-II enzymes are all inhibited through phosphorylation by PknA, PknB and other STPKs89–93.”
What the sources say
- Disputedcites [89] Molle, V., Brown, A. K., Besra, G. S., Cozzone, A. J. & Kremer, L. The condensing activities of the Mycobacterium tuberculosis type II fatty acid synthase are differentially regulated by phosphorylation. J. Biol. Chem. 281, 30094–30103 (2006). sourceExperimental — accuracy not yet measured
The STPK-mediated Phosphorylation section reports that PknA and other STPKs phosphorylate the three FAS-II components tested. But the discussion (p. 30101) says phosphorylation reduces KasA activity while enhancing KasB activity. The paper therefore contradicts the claim that the enzymes are all inhibited. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [90] Vilchèze, C. et al. Phosphorylation of KasB regulates virulence and acid-fastness in Mycobacterium tuberculosis. PLOS Pathog. 10, e1004115 (2014). sourceExperimental — accuracy not yet measured
The Introduction (page not provided) says that most essential enzymes in the FASII central core are phosphorylated by STPKs and that phosphorylation inhibits their activity at least in vitro. The Results (page not provided) show that KasB can be phosphorylated by PknA, PknB and other kinases, but the paper does not establish that all FASII enzymes are inhibited by those kinases. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [91] Slama, N. et al. Negative regulation by Ser/Thr phosphorylation of HadAB and HadBC dehydratases from Mycobacterium tuberculosis type II fatty acid synthase system. Biochem. Biophys. Res. Commun. 412, 401–406 (2011). source
- Disputedcites [92] Khan, S. et al. Phosphorylation of enoyl-acyl carrier protein reductase inha impacts mycobacterial growth and survival. J. Biol. Chem. 285, 37860–37871 (2010). sourceExperimental — accuracy not yet measured
The passage labeled Abstract says phosphorylation negatively affects KasA activity but enhances KasB activity. KasB is a FAS-II enzyme, so the paper contradicts the claim that all FAS-II enzymes are inhibited by phosphorylation. (LLM, conf=0.90)
Checked by a reasoning model — may be wrong.
- Partly supportedcites [93] Veyron-Churlet, R., Zanella-Cléon, I., Cohen-Gonsaud, M., Molle, V. & Kremer, L. Phosphorylation of the Mycobacterium tuberculosis β-ketoacyl-acyl carrier protein reductase MabA regulates mycolic acid biosynthesis. J. Biol. Chem. 285, 12714–12725 (2010). sourceExperimental — accuracy not yet measured
The MabA phosphorylation results and Discussion show that several FAS-II enzymes are STPK substrates; MabA is phosphorylated in vitro by PknA, PknB, and other kinases, and a phosphomimetic MabA variant has reduced activity. But the Discussion says the effect of phosphorylation on mtFabD activity is unknown and whether HadABC and InhA are STPK substrates remains unresolved. The paper therefore does not support the claim that all FAS-II enzymes are inhibited through phosphorylation. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“MtrA and PknA or PknB activate transcription of fbpB and fbpA65.”
What the sources say
- Disputedcites [65] Carette, X. et al. Multisystem analysis of Mycobacterium tuberculosis reveals kinase-dependent remodeling of the pathogen-environment interface. mBio 9, (2018). sourceExperimental — accuracy not yet measured
In Results, under “Thr213 phosphorylation disrupts MtrA binding to the fbpB promoter” (page unavailable), the paper describes MtrA as a repressor, not an activator, of fbpB transcription. It reports that PknA/PknB inhibition increases MtrA binding and repression of fbpB. A separate Results passage reports decreased fbpA expression during kinase inhibition but does not establish that MtrA activates fbpA. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“We can learn about these states from chronic stage mouse experiments48 and from in vitro experiments in starvation, late stationary phase and oxygen deprivation49, during which growth stasis is observed.”
What the sources say
- Supportedcites [48] Zhang, Y. J. et al. Tryptophan biosynthesis protects mycobacteria from CD4 T-cell-mediated killing. Cell 155, 1296–1308 (2013). source
The Results section (page unavailable) describes mouse infection experiments with measurements at days 10 and 45, including genes needed to sustain long-term growth in vivo. This supports the chronic-stage mouse-experiment portion attached to citation 48; the in vitro conditions are attached to citation 49 and are not assessed here. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [49] Wayne, L. G. & Hayes, L. G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence. Infect. Immun. 64, 8 (1996). source
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“M. tuberculosis is thought to replicate, albeit slowly, during chronic mouse and subclinical primate infection46,47; thus, when we refer to 'stasis', we mean that growth and death are in equilibrium, not that growth is arrested.”
What the sources say
- Partly supportedcites [46] Gill, W. P. et al. A replication clock for Mycobacterium tuberculosis. Nat. Med. 15, 211–214 (2009). sourceExperimental — accuracy not yet measured
The mouse-infection results report continued replication during chronic infection, with a calculated generation time of four days at 16 weeks. The paper does not establish replication during subclinical primate infection; it says the authors plan to study nonhuman primates. Thus it supports the mouse portion, but not the primate portion, of the attributed claim. (LLM, conf=0.89)
- Partly supportedcites [47] Ford, C. B. et al. Use of whole genome sequencing to estimate the mutation rate of Mycobacterium tuberculosis during latent infection. Nat. Genet. 43, 482–486 (2011). sourceExperimental — accuracy not yet measured
The passage on replication during infection (labeled Abstract; no page given) reports slow replication in mice after ten weeks of chronic infection. For clinically latent primates, it says replication is thought to slow dramatically or cease entirely and that generation time is unknown; it therefore does not establish that slow replication continues in that setting. (LLM, conf=0.83)
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Differential transcription of these arabinotransferases may help keep LAM synthe- sis high14 when arabinogalactan synthesis slows on entry into stasis in the chronic phase.”
What the sources say
- Supportedcites [14] Bacon, J. et al. Non-replicating Mycobacterium tuberculosis elicits a reduced infectivity profile with corresponding modifications to the cell wall and extracellular matrix. PLOS ONE 9, e87329 (2014). source
The citation is attached to the claim that LAM synthesis remains high. In the Discussion (‘The composition of extracellular material’; page unavailable), the paper reports increasing LAM quantity during nutrient depletion and up-regulation of LAM-biosynthesis genes from early through late stationary phase. The comparison with slowing arabinogalactan synthesis is not the part directly cited. (LLM, conf=0.87)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
38 more claims · 21 with their cited sources checked
Create a free account to see all 92 claims and to verify the 2 references still open.
- It may state two separate claims as one. 47
- Probably not a substantial claim. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Author contributions
“E.R.B. provided critical feedback and suggested changes.”
“Charles L. Dulberger1,2, Eric J. Rubin 2,3 and Cara C. Boutte 4*”
Citations
Cites
Brennan, P. J., & Nikaido, H. (1995) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.64.070195.000333 · Cited by 1,985
Betts, J. C., Lukey, P. T., Robb, L. C., McAdam, R. A., & Duncan, K. (2002) · Molecular Microbiology · doi:10.1046/j.1365-2958.2002.02779.x · Cited by 1,395
The Immune Response in Tuberculosis
O'Garra, A., Redford, P. S., McNab, F. W., Bloom, C. I., Wilkinson, R. J., & Berry, M. P. R. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095939 · Cited by 1,342
Wayne, L. G., & Hayes, L. G. (1996) · Infection and Immunity · doi:10.1128/iai.64.6.2062-2069.1996 · Cited by 1,141
M. tuberculosis and M. leprae Translocate from the Phagolysosome to the Cytosol in Myeloid Cells
van der Wel, N., Hava, D., Houben, D., Fluitsma, D., van Zon, M., Pierson, J., Brenner, M., & Peters, P. J. (2007) · Cell · doi:10.1016/j.cell.2007.05.059 · Cited by 960
Direct recognition of the mycobacterial glycolipid, trehalose dimycolate, by C-type lectin Mincle
Ishikawa, E., Ishikawa, T., Morita, Y. S., Toyonaga, K., Yamada, H., Takeuchi, O., Kinoshita, T., Akira, S., Yoshikai, Y., & Yamasaki, S. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20091750 · Cited by 792
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis
Makarov, V., Manina, G., Mikusova, K., Möllmann, U., Ryabova, O., Saint-Joanis, B., Dhar, N., Pasca, M. R., Buroni, S., Lucarelli, A. P., et al. (2009) · Science · doi:10.1126/science.1171583 · Cited by 740
Role of the Major Antigen of Mycobacterium tuberculosis in Cell Wall Biogenesis
Belisle, J. T., Vissa, V. D., Sievert, T., Takayama, K., Brennan, P. J., & Besra, G. S. (1997) · Science · doi:10.1126/science.276.5317.1420 · Cited by 734
Mycolic Acids: Structures, Biosynthesis, and Beyond
Marrakchi, H., Lanéelle, M.-A., & Daffé, M. (2014) · Chemistry & Biology · doi:10.1016/j.chembiol.2013.11.011 · Cited by 623
Hoffmann, C., Leis, A., Niederweis, M., Plitzko, J. M., & Engelhardt, H. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0709530105 · Cited by 596
Cited by
Allué-Guardia, A., García, J. I., & Torrelles, J. B. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.612675 · Cited by 223
“tb interacts with the host immune system and its potential implications for antibiotic resistance (Dulberger et al., 2020).”
BackgroundPathogenicity and virulence of Mycobacterium tuberculosis
Rahlwes, K. C., Dias, B. R. S., Campos, P. C., Alvarez-Arguedas, S., & Shiloh, M. U. (2023) · Virulence · doi:10.1080/21505594.2022.2150449 · Cited by 207
“Peptidoglycan and arabinogalactan within the cell envelope play a critical role for Mtb infection and the overall impermeability of its cell envelope [71,185,186].”
BackgroundPhysiological Functions of Bacterial “Multidrug” Efflux Pumps
Henderson, P. J. F., Maher, C., Elbourne, L. D. H., Eijkelkamp, B. A., Paulsen, I. T., & Hassan, K. A. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c01226 · Cited by 204
CHARMM-GUI Membrane Builder: Past, Current, and Future Developments and Applications
Feng, S., Park, S., Choi, Y. K., & Im, W. (2023) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.2c01246 · Cited by 186
Thacker, V. V., Dhar, N., Sharma, K., Barrile, R., Karalis, K., & McKinney, J. D. (2020) · eLife · doi:10.7554/elife.59961 · Cited by 163
Metadata
- Authors
- Dulberger, C. L., Rubin, E. J., & Boutte, C. C.
- Affiliations
- Harvard University (US)
- The University of Texas at Arlington (US)
- Corresponding author
- Boutte, Cara C.
- Venue
- Nature Reviews Microbiology
- Published
- 2019-11-14
- Volume
- 18
- Issue
- 1
- Pages
- 47-59
- ISSN
- 1740-1526 (ISSN-L)
- 1740-1534
- OpenAlex
- W2986825963
- Semantic Scholar
- 214eb9774ad8675eeecc7a87eaea81381df3850f
- Cited by
- 365
- References
- 160
- Citations by year
- 2026: 50 · 2025: 75 · 2024: 48 · 2023: 55 · 2022: 48 · 2021: 49 · 2020: 39 · 2019: 1
- FWCI
- 4.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Microbiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of General Medical Sciences (R15GM131317)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Tuberculosis Research and Epidemiology
- Health Sciences › Medicine › Epidemiology › Mycobacterium research and diagnosis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Bacterial Genetics and Biotechnology
- Keywords
- Mycobacterium tuberculosis, mycobacterial cell envelope, cell wall metabolism, surface lipids, immune evasion, antibiotic resistance, antibiotic susceptibility, host adaptation, macrophages, tuberculosis infection
- MeSH terms
- Animals, Cell Wall, Drug Tolerance, Humans, Immunity, Innate, Mycobacterium tuberculosis, Lipid Metabolism, Host-Pathogen Interactions, Adaptive Immunity, Immune Evasion
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The mycobacterial cell envelope — a moving target. https://app.cochat.ai/papers/10.1038/s41579-019-0273-7
- The paper
- Dulberger, C. L., Rubin, E. J., & Boutte, C. C. (2020). The mycobacterial cell envelope — a moving target. Nature Reviews Microbiology. https://doi.org/10.1038/s41579-019-0273-7
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.